Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Lazzeri

Showing results (211-220 of 327) with videos related to

Pageof 33
Sort By:
World Journal of Urology|April 15, 2021
Assessing in-hospital morbidity after urethroplasty using the European Association of Urology Quality Criteria for standardized reportingMarco Bandini, Guido Barbagli, Riccardo Leni, et al.
Minerva Urology and Nephrology|August 2, 2021
Active surveillance for recurrent non-muscle invasive bladder cancer: which lessons have we learned during COVID-19 pandemic?Marco Paciotti, Roberto Contieri, Vittorio Fasulo, et al.
European Urology|April 13, 2011
Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical settingGiorgio Guazzoni, Luciano Nava, Massimo Lazzeri, et al.
Urologic Oncology|June 29, 2021
The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: A single institutional analysisPier Paolo Avolio, Giovanni Lughezzani, Marco Paciotti, et al.
European Urology Focus|October 18, 2020
Diagnostic Accuracy of Microultrasound in Patients with a Suspicion of Prostate Cancer at Magnetic Resonance Imaging: A Single-institutional Prospective StudyGiovanni Lughezzani, Davide Maffei, Alberto Saita, et al.
Urologic Oncology|December 3, 2020
Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failureRodolfo Hurle, Roberto Contieri, Paolo Casale, et al.
European Urology Focus|December 4, 2020
Multi-institutional Retrospective Validation and Comparison of the Simplified PADUA REnal Nephrometry System for the Prediction of Surgical Success of Robot-assisted Partial NephrectomyPietro Diana, Giovanni Lughezzani, Alessandro Uleri, et al.
Science Translational Medicine|January 7, 2021
Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancerBianca Oresta, Chiara Pozzi, Daniele Braga, et al.
Therapeutic Advances in Urology|April 2, 2016
Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidenceMassimo Lazzeri, Rodolfo Hurle, Paolo Casale, et al.
World Journal of Urology|June 30, 2026
AI-driven model for early failure prediction after HIFU integrating immediate post-ablation ultrasound and clinical dataLudovica Cella, Pier Paolo Avolio, Luca Mascaro, et al.
Pageof 33

Showing results (211-220 of 327) with videos related to

Sort By:
Pageof 33
World Journal of Urology|April 15, 2021
Assessing in-hospital morbidity after urethroplasty using the European Association of Urology Quality Criteria for standardized reportingMarco Bandini, Guido Barbagli, Riccardo Leni, et al.
Minerva Urology and Nephrology|August 2, 2021
Active surveillance for recurrent non-muscle invasive bladder cancer: which lessons have we learned during COVID-19 pandemic?Marco Paciotti, Roberto Contieri, Vittorio Fasulo, et al.
European Urology|April 13, 2011
Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical settingGiorgio Guazzoni, Luciano Nava, Massimo Lazzeri, et al.
Urologic Oncology|June 29, 2021
The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: A single institutional analysisPier Paolo Avolio, Giovanni Lughezzani, Marco Paciotti, et al.
European Urology Focus|October 18, 2020
Diagnostic Accuracy of Microultrasound in Patients with a Suspicion of Prostate Cancer at Magnetic Resonance Imaging: A Single-institutional Prospective StudyGiovanni Lughezzani, Davide Maffei, Alberto Saita, et al.
Urologic Oncology|December 3, 2020
Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failureRodolfo Hurle, Roberto Contieri, Paolo Casale, et al.
European Urology Focus|December 4, 2020
Multi-institutional Retrospective Validation and Comparison of the Simplified PADUA REnal Nephrometry System for the Prediction of Surgical Success of Robot-assisted Partial NephrectomyPietro Diana, Giovanni Lughezzani, Alessandro Uleri, et al.
Science Translational Medicine|January 7, 2021
Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancerBianca Oresta, Chiara Pozzi, Daniele Braga, et al.
Therapeutic Advances in Urology|April 2, 2016
Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidenceMassimo Lazzeri, Rodolfo Hurle, Paolo Casale, et al.
World Journal of Urology|June 30, 2026
AI-driven model for early failure prediction after HIFU integrating immediate post-ablation ultrasound and clinical dataLudovica Cella, Pier Paolo Avolio, Luca Mascaro, et al.
Pageof 33